Inflammatory bowel disease in juvenile idiopathic arthritis patients treated with biologics

Journal of Rheumatology

Volumn 42, Issue 11, 2015, Pages 2160-2165

  Barthel, Deborah ^a   Ganser, Gerd ^b   Kuester, Rolf Michael ^c   Onken, Nils ^d   Minden, Kirsten ^e   Girschick, Hermann Josef ^f   Hospach, Anton ^g   Horneff, Gerd ^a  

^a Asklepios Klinik Sankt Augustin   (Germany)

^b Abt Kinder und Jugendrheumatologie   (Germany)

^c Asklepios Hospital Hamburg   (Germany)

^d Pediatric Practice   (Germany)

^e DEUTSCHES RHEUMA FORSCHUNGSZENTRUM   (Germany)

^f VIVANTES KLINIKUM IM FRIEDRICHSHAIN   (Germany)

^g KLINIKUM STUTTGART   (Germany)

Author keywords

Biologics; Etanercept methotrexate; Inflammatory bowel disease; Juvenile idiopathic arthritis

Indexed keywords

ABATACEPT; ADALIMUMAB; ANTINUCLEAR ANTIBODY; AZATHIOPRINE; BIOLOGICAL PRODUCT; CORTICOSTEROID; ETANERCEPT; HLA B27 ANTIGEN; INFLIXIMAB; LEFLUNOMIDE; METHOTREXATE; NONSTEROID ANTIINFLAMMATORY AGENT; RECOMBINANT INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; RHEUMATOID FACTOR; SALAZOSULFAPYRIDINE; TOCILIZUMAB;

ADOLESCENT; ARTHRITIS; ARTICLE; CHILD; COHORT ANALYSIS; COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; CROHN DISEASE; DISEASE ASSOCIATION; DISEASE REGISTRY; DRUG EXPOSURE; DRUG WITHDRAWAL; ENTHESITIS; FEMALE; GERMANY; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; INCIDENCE; INFLAMMATORY BOWEL DISEASE; JUVENILE RHEUMATOID ARTHRITIS; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; OBSERVATIONAL STUDY; ONSET AGE; PEDIATRICS; POLYARTHRITIS; PRESCHOOL CHILD; PRIORITY JOURNAL; PROSPECTIVE STUDY; PSORIATIC ARTHRITIS; REMISSION; SCHOOL CHILD; ULCERATIVE COLITIS; AGE DISTRIBUTION; ARTHRITIS, JUVENILE; CHEMICALLY INDUCED; COMORBIDITY; COMPARATIVE STUDY; INFLAMMATORY BOWEL DISEASES; PATHOPHYSIOLOGY; PROGNOSIS; REGISTER; RISK ASSESSMENT; SEVERITY OF ILLNESS INDEX; SEX RATIO;

ADOLESCENT; AGE DISTRIBUTION; ARTHRITIS, JUVENILE; BIOLOGICAL PRODUCTS; CHILD; CHILD, PRESCHOOL; COHORT STUDIES; COMORBIDITY; ETANERCEPT; FEMALE; GERMANY; HUMANS; INCIDENCE; INFLAMMATORY BOWEL DISEASES; MALE; METHOTREXATE; PROGNOSIS; PROSPECTIVE STUDIES; REGISTRIES; RISK ASSESSMENT; SEVERITY OF ILLNESS INDEX; SEX DISTRIBUTION;

EID: 84946594999     PISSN: 0315162X     EISSN: 14992752     Source Type: Journal    
DOI: 10.3899/jrheum.140472     Document Type: Article

References (41)

1. Manners PJ, Bower C. Worldwide prevalence of juvenile arthritis why does it vary so much? J Rheumatol 2002;29:1520-30.
2. Danner S, Sordet C, Terzic J, Donato L, Velten M, Fischbach M, et al. Epidemiology of juvenile idiopathic arthritis in Alsace, France. J Rheumatol 2006;33:1377-81.
3. Berntson L, Fasth A, Andersson-Gäre B, Kristinsson J, Lahdenne P, Marhaug G, et al; Nordic Study Group. Construct validity of ILAR and EULAR criteria in juvenile idiopathic arthritis: a population based incidence study from the Nordic countries. International League of Associations for Rheumatology. European League Against Rheumatism. J Rheumatol 2001;28:2737-43.
4. Beukelman T, Patkar NM, Saag KG, Tolleson-Rinehart S, Cron RQ, DeWitt EM, et al. 2011 American College of Rheumatology recommendations for the treatment of juvenile idiopathic arthritis: initiation and safety monitoring of therapeutic agents for the treatment of arthritis and systemic features. Arthritis Care Res 2011;63:465-82.
5. Horneff G, Foeldvari I, Minden K, Moebius D, Hospach T. Report on malignancies in the German juvenile idiopathic arthritis registry. Rheumatology 2011;50:230-6.
6. Dueckers G, Guellac N, Arbogast M, Dannecker G, Foeldvari I, Frosch M, et al. Evidence and consensus based GKJR guidelines for the treatment of juvenile idiopathic arthritis. Clin Immunol 2012;142:176-93.
7. Klein A, Kaul I, Foeldvari I, Ganser G, Urban A, Horneff G. Efficacy and safety of oral and parenteral methotrexate therapy in children with juvenile idiopathic arthritis: an observational study with patients from the German Methotrexate Registry. Arthritis Care Res 2012;64:1349-56.
8. Lovell DJ, Giannini EH, Reiff A, Cawkwell GD, Silverman ED, Nocton JJ, et al. Etanercept in children with polyarticular juvenile rheumatoid arthritis. Pediatric Rheumatology Collaborative Study Group. N Engl J Med 2000;342:763-9.
9. Lovell DJ, Reiff A, Ilowite NT, Wallace CA, Chon Y, Lin SL, et al; Pediatric Rheumatology Collaborative Study Group. Safety and efficacy of up to eight years of continuous etanercept therapy in patients with juvenile rheumatoid arthritis. Arthritis Rheum 2008;58:1496-504.
10. Quartier P, Taupin P, Bourdeaut F, Lemelle I, Pillet P, Bost M, et al. Efficacy of etanercept for the treatment of juvenile idiopathic arthritis according to the onset type. Arthritis Rheum 2003; 48:1093-101.
11. Horneff G, De Bock F, Foeldvari I, Girschick HJ, Michels H, Moebius D, et al; German and Austrian Paediatric Rheumatology Collaborative Study Group. Safety and efficacy of combination of etanercept and methotrexate compared to treatment with etanercept only in patients with juvenile idiopathic arthritis (JIA): preliminary data from the German JIA Registry. Ann Rheum Dis 2009; 68:519-25.
12. Brennan FM, Feldmann M. Cytokines in autoimmunity. Curr Opin Immunol 1992;4:754-9.
13. van Dijken TD, Vastert SJ, Gerloni VM, Pontikaki I, Linnemann K, Girschick H, et al. Development of inflammatory bowel disease in patients with juvenile idiopathic arthritis treated with etanercept. J Rheumatol 2011;38:1441-6.
14. Wiegering V, Morbach H, Dick A, Girschick HJ. Crohn's disease during etanercept therapy in juvenile idiopathic arthritis: a case report and review of the literature. Rheumatol Int 2010;30:801-4.
15. Toussirot É, Houvenagel É, Goëb V, Fouache D, Martin A, Le Dantec P, et al. Development of inflammatory bowel disease during anti-TNF-α therapy for inflammatory rheumatic disease: a nationwide series. Joint Bone Spine 2012;79:457-63.
16. Gerloni V, Pontikaki I, Gattinara M, Fantini F. Focus on adverse events of tumour necrosis factor alpha blockade in juvenile idiopathic arthritis in an open monocentric long-term prospective study of 163 patients. Ann Rheum Dis 2008;67:1145-52.
17. Tarkiainen M, Tynjälä P, Vähäsalo P, Lahdenne P. Occurrence of inflammatory bowel disease in four patients with juvenile idiopathic arthritis receiving etanercept or infliximab. Scand J Rheumatol 2011;40:150-2.
18. Breese EJ, Michie CA, Nicholls SW, Murch SH, Williams CB, Domizio P, et al. Tumor necrosis factor alpha-producing cells in the intestinal mucosa of children with inflammatory bowel disease. Gastroenterology 1994;106:1455-66.
19. Peyrin-Biroulet L, Deltenre P, de Suray N, Branche J, Sandborn WJ, Colombel JF. Efficacy and safety of tumor necrosis factor antagonists in Crohn's disease: Meta-analysis of placebo-controlled trials. Clin Gastroenterol Hepatol 2008;6:644-53.
20. Sandborn WJ, Hanauer SB, Katz S, Safdi M, Wolf DG, Baerg RD, et al. Etanercept for active Crohn's disease: a randomized, double-blind, placebo-controlled trial. Gastroenterology 2001;121:1088-94.
21. Mielants H, Veys EM, Cuvelier C, De Vos M, Goemaere S, De Clercq L, et al. The evolution of spondyloarthropathies in relation to gut histology. III. Relation between gut and joint. J Rheumatol 1995;22:2279-84.
22. Horneff G, Schmeling H, Biedermann T, Foeldvari I, Ganser G, Girschick HJ, et al. The German etanercept registry for treatment of juvenile idiopathic arthritis. Ann Rheum Dis 2004;63:1638-44.
23. Sawczenko A, Sandhu BK, Logan RF, Jenkins H, Taylor CJ, Mian S, et al. Prospective survey of childhood inflammatory bowel disease in the British Isles. Lancet 2001;357:1093-4.
24. Levine A, Koletzko S, Turner D, Escher JC, Cucchiara S, de Ridder L, et al; European Society of Pediatric Gastroenterology, Hepatology, and Nutrition. ESPGHAN revised porto criteria for the diagnosis of inflammatory bowel disease in children and adolescents. J Pediatr Gastroenterol Nutr 2014;58:795-806.
25. Auvin S, Molinié F, Gower-Rousseau C, Brazier F, Merle V, Grandbastien B, et al. Incidence, clinical presentation and location at diagnosis of pediatric inflammatory bowel disease: a prospective population-based study in northern France (1988-1999). J Pediatr Gastroenterol Nutr 2005;41:49-55.
26. Orel R, Kamhi T, Vidmar G, Mamula P. Epidemiology of pediatric chronic inflammatory bowel disease in central and western Slovenia, 1994-2005. J Pediatr Gastroenterol Nutr 2009;48:579-86.
27. Benchimol EI, Guttmann A, Griffiths AM, Rabeneck L, Mack DR, Brill H, et al. Increasing incidence of paediatric inflammatory bowel disease in Ontario, Canada: evidence from health administrative data. Gut 2009;58:1490-7.
28. Jakobsen C, Paerregaard A, Munkholm P, Faerk J, Lange A, Andersen J, et al. Pediatric inflammatory bowel disease: increasing incidence, decreasing surgery rate, and compromised nutritional status: A prospective population-based cohort study 2007-2009. Inflamm Bowel Dis 2011;17:2541-50.
29. Arvonen M, Vähäsalo P, Turunen S, Salo HM, Mäki M, Laurila K, et al. Altered expression of intestinal human leucocyte antigen D-related and immune signalling molecules in juvenile idiopathic arthritis. Clin Exp Immunol 2012;170:266-73.
30. Turner D, Grossman AB, Rosh J, Kugathasan S, Gilman AR, Baldassano R, et al. Methotrexate following unsuccessful thiopurine therapy in pediatric Crohn's disease. Am J Gastroenterol 2007;102:2804-12.
31. Ardizzone S, Bollani S, Manzionna G, Imbesi V, Colombo E, Bianchi Porro G. Comparison between methotrexate and azathioprine in the treatment of chronic active Crohn's disease: a randomised, investigator-blind study. Dig Liver Dis 2003;35:619-27.
32. Fouache D, Goëb V, Massy-Guillemant N, Avenel G, Bacquet-Deschryver H, Kozyreff-Meurice M, et al. Paradoxical adverse events of anti-tumour necrosis factor therapy for spondyloarthropathies: a retrospective study. Rheumatology 2009;48:761-4.
33. Fiorino G, Danese S, Pariente B, Allez M. Paradoxical immune-mediated inflammation in inflammatory bowel disease patients receiving anti-TNF-α agents. Autoimmun Rev 2014; 13:15-9.
34. Van den Brande JM, Braat H, van den Brink GR, Versteeg HH, Bauer CA, Hoedemaeker I, et al. Infliximab but not etanercept induces apoptosis in lamina propria T-lymphocytes from patients with Crohn's disease. Gastroenterology 2003;124:1774-85.
35. Zou J, Rudwaleit M, Brandt J, Thiel A, Braun J, Sieper J. Up regulation of the production of tumour necrosis factor alpha and interferon gamma by T cells in ankylosing spondylitis during treatment with etanercept. Ann Rheum Dis 2003;62:561-4.
36. Shen C, Assche G V, Colpaert S, Maerten P, Geboes K, Rutgeerts P, et al. Adalimumab induces apoptosis of human monocytes: a comparative study with infliximab and etanercept. Aliment Pharmacol Ther 2005:21:251-8.
37. Berg L, Lampa J, Rogberg S, van Vollenhoven R, Klareskog L. Increased peripheral T cell reactivity to microbial antigens and collagen type II in rheumatoid arthritis after treatment with soluble TNFalpha receptors. Ann Rheum Dis 2001;60:133-9.
38. García Rodríguez LA, González-Pérez A, Johansson S, Wallander MA. Risk factors for inflammatory bowel disease in the general population. Aliment Pharmacol Ther 2005;22:309-15.
39. Bernstein CN, Wajda A, Blanchard JF The clustering of other chronic inflammatory diseases in inflammatory bowel disease: a population-based study. Gastroenterology 2005:129:827-36.
40. Kappelman MD, Galanko JA, Porter CQ, Sandler RS Association of paediatric inflammatory bowel disease with other immune-mediated diseases. Arch Dis Child 2011:96:1042-6.
41. Lees CW, Barrett JC, Parkes M, Satsangi J. New IBD genetics: common pathways with other diseases. Gut 2011:60;1739-53.